Opiant Pharmaceuticals (OPNT) Peer Comparison
$20.65
$0.00 (0.00%)As on 02-Mar-2023 09:30EDT
Market cap
$109 Mln
Revenue (TTM)
$18 Mln
P/E Ratio
--
P/B Ratio
5.1
Div. Yield
0 %
Edit
| Opiant Pharmaceuticals (OPNT) | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | Inventiva Sa (IVA) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
109 | 2,928 | 2,262 | 2,152 | 1,111 |
Revenue ($ Mln) |
18 | 450 | 120 | 549 | 4 |
Net Profit ($ Mln) |
-33.09 | -188.21 | -57.50 | 17.88 | -340.16 |
Net Margin (%) |
-186.63 | -41.86 | -144.33 | 3.26 | -540.52 |
RoE (%) |
-110.73 | -28.46 | -9.86 | 1.43 | 501.41 |
Price to Earnings |
-- | -- | -- | 123.80 | -- |
Price-To-Book |
5.09 | 4.96 | 4.15 | 1.71 | 2.10 |
Income Statement ($ Mln)
| Opiant Pharmaceuticals (OPNT) | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | Inventiva Sa (IVA) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
40.73 | 215.04 | 10.21 | 426.41 | 12.18 |
|
Cost of Revenue
|
9.07 | 74.02 | 63.57 | 311.10 | 1.00 |
|
Gross Profit
|
31.66 | 141.02 | -53.36 | 115.31 | 12.18 |
|
Operating Expenses
|
26.50 | 545.38 | 90.79 | 834.10 | 69.29 |
|
Operating Profit (EBIT)
|
5.16 | -404.36 | -80.57 | -718.80 | -57.11 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
3.03 | -443.29 | -91.59 | -360.67 | -54.29 |
|
Provision for Tax
|
0.02 | 0.22 | -0.24 | -0.28 | -0.02 |
|
Profit after Tax (Net Income)
|
3.01 | -443.29 | -91.35 | -360.84 | -54.27 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
3.01 | -443.29 | -91.35 | -360.84 | -49.64 |
Liabilities ($ Mln)
| Opiant Pharmaceuticals (OPNT) | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | Inventiva Sa (IVA) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
46.84 | 1,045.60 | 497.04 | 610.37 | 45.48 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
16.74 | 34.70 | 113.73 | 38.67 | 39.83 |
|
Current Liabilities
|
6.85 | 139.84 | 51.37 | 353.90 | 30.70 |
|
Total Liabilities
|
70.43 | 1,220.14 | 662.14 | 1,029.45 | 116.00 |
Assets ($ Mln)
| Opiant Pharmaceuticals (OPNT) | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | Inventiva Sa (IVA) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
1.27 | 95.80 | 592.31 | 189.56 | 9.62 |
|
Current Assets
|
69.16 | 1,124.34 | 69.84 | 839.89 | 106.38 |
|
Total Assets
|
70.43 | 1,220.14 | 662.14 | 1,029.45 | 116.00 |
|
Total Debt*
|
17.08 | 20.39 | 106.91 | 27.01 | 34.51 |
|
Net Current Assets
|
62.31 | 984.49 | 18.46 | 485.99 | 75.68 |
Cashflow ($ Mln)
| Opiant Pharmaceuticals (OPNT) | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | Inventiva Sa (IVA) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
1.93 | -367.64 | -65.78 | -268.60 | -44.93 |
|
Cash Flow from Investing Activities
|
-15.01 | 420.02 | -0.23 | 296.59 | 8.87 |
|
Cash from Financing Activities
|
2.72 | -1.73 | -9.87 | -82.76 | 37.27 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Opiant Pharmaceuticals (OPNT) | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | Inventiva Sa (IVA) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
5.08 | -36.02 | -14.15 | -43.39 | -60.65 |
|
ROE (%)
|
7.31 | -36.55 | -16.94 | -45.18 | -80.80 |
|
ROA (%)
|
4.59 | -31.33 | -12.99 | -30.04 | -45.61 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
7.39 | -206.14 | -894.59 | -84.62 | -445.64 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Opiant Pharmaceuticals (OPNT) | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | Inventiva Sa (IVA) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
0.49 | 0.49 | 0.37 | 0.20 | 1.90 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
261.64 | 37.08 | 7.55 | -85.38 | -9.34 |
|
EPS Growth (%)
|
-- | 0.37 | 0.08 | -0.88 | -0.03 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Opiant Pharmaceuticals (OPNT) | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | Inventiva Sa (IVA) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-- | -66.48 | -1.58 | -6.92 | -3.45 |
|
Price / Book Value
|
-- | 28.19 | 0.29 | 4.09 | 4.12 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-6.15 | -65.50 | -2.50 | -5.26 | -2.42 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Opiant Pharmaceuticals (OPNT) | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | Inventiva Sa (IVA) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.36 | 0.02 | 0.22 | 0.04 | 0.76 |
|
Short term debt to equity ratio
|
0.01 | 0.01 | 0.02 | 0.01 | 0.13 |
|
Current Ratio
|
10.10 | 8.04 | 1.36 | 2.37 | 3.47 |
|
Quick Ratio
|
-- | 7.81 | 1.57 | 2.21 | 3.45 |
|
Interest Coverage
|
2.42 | -30.38 | -4.68 | -628.48 | -80.78 |
Operating Efficiency Ratios
| Opiant Pharmaceuticals (OPNT) | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | Inventiva Sa (IVA) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
32.73 | 22.59 | 43.12 | 29.72 | 2.29 |
|
Asset Turnover
|
0.62 | 0.15 | 0.01 | 0.36 | 0.10 |
|
Receivable days
|
99.72 | 87.80 | 160.84 | 117.55 | 177.93 |
|
Inventory Days
|
-- | 124.78 | -1.45 | 54.27 | 140.41 |
|
Payable days
|
127.63 | 474.06 | 122.60 | 65.92 | 6,233.29 |
|
Cash Conversion Cycle
|
-- | -261.49 | 36.79 | 105.89 | -5,914.95 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
